BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Auxogyn, Inc. Announces European Expansion of New Non-Invasive Early Embryo Viability Assessment (Eeva(™)) Test With Availability at First Clinic in Ireland


1/24/2013 8:38:53 AM

MENLO PARK, CA--(Marketwire - January 24, 2013) -

Auxogyn Inc. today announced that Sims IVF is the first fertility clinic in Ireland to offer patients the Early Embryo Viability Assessment (Eeva) Test. The Eeva Test is designed to improve in vitro fertilization (IVF) outcomes by providing clinicians and patients with objective information that will enable them to predict embryo viability with a new level of accuracy. The Eeva Test uses intelligent computer vision software to measure key scientifically and clinically validated cell-division parameters from video images. It is the first and only non-invasive IVF test clinically proven to improve the accuracy of selecting embryos that will likely grow to the blastocyst stage, a critical milestone in embryo development.

"We are proud to be the first clinic in Ireland to offer the Eeva Test, giving our patients the best chance at a successful embryo implantation," said Dr. David Walsh, director and consultant gynaecologist at Sims IVF. "The Eeva Test is the most significant breakthrough in IVF in recent decades. Since intra-cytoplasmic sperm injection (ICSI) in the early 1990's, we have been waiting for a new technology that could have a transformative effect on IVF success rates. Eeva allows us to select embryos based on factual, objective scientific evidence, not just on how the embryos look -- something that has not been available to us until now."

"With the expansion of Eeva into Ireland, more patients will now have access to the first and only non-invasive test that delivers consistent, objective and actionable information to help identify viable embryos and determine which ones offer the greatest potential," said Lissa Goldenstein, president and chief executive officer of Auxogyn. "Our goal in developing Eeva is to help patients achieve a successful pregnancy. We expect that the availability of Eeva will help IVF clinics optimize the treatment path for their patients who are undergoing IVF procedures."

Appointments for the new test are available from Sims IVF by calling 011 353 01 208 0710 or visiting www.sims.ie. Sims IVF is holding Eeva Information evenings on 7 & 13 February 2013 at Sims IVF Clonskeagh. Visit www.sims.ie for further details.

About IVF
Infertility affects one out of every six couples. The demand for assisted reproduction tools and procedures is growing worldwide due to higher infertility rates caused by an increasing maternal age as more women are starting families later in life. This worldwide growth is occurring despite the significant cost per cycle and the low success rate, with approximately one-third of cycles resulting in a live birth. This necessitates the transfer of multiple embryos and/or conducting multiple cycles, leading to greater physical, emotional, practical and financial costs, before determining if pregnancy can be achieved.

About the Early Embryo Viability Assessment (Eeva) Test
The Eeva Test is designed to improve IVF outcomes by providing clinicians and patients with objective information that will enable them to more confidently select embryo(s) for transfer. Eeva's proprietary software automatically analyses embryo development against scientifically and clinically validated cell-division parameters discovered by Stanford University researchers. The Eeva test not only provides novel quantitative information, but also ensures consistent measurements to assess embryo development versus the manual methods used today in clinical practice. With Eeva's quantitative data for each embryo's potential development, IVF clinics may be able to optimise the treatment path for their patients undergoing IVF procedures.

The safety and efficacy of Eeva were validated in a prospective, multi-center, 54-patient clinical trial with 755 embryos. Embryologists using Eeva were significantly able to improve their ability to identify non-viable embryos (85 percent of the time vs. 60 percent of the time when using traditional methods). Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists. Results of this study were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting in Istanbul, Turkey.

Eeva is currently approved and available for use only in the EU. For more information about Eeva, visit eevaivf.com or follow Eeva on Twitter @EevaIVF.

About Auxogyn
Auxogyn is revolutionising the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The Company's flagship product, the Eeva™ Test, delivers consistent, objective and quantitative information regarding embryo viability that IVF clinicians and infertility patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information regarding Auxogyn, please visit www.auxogyn.com and follow us on Twitter @Auxogyn.


Contact:
Nicole Foderero
BrewLife
(415) 946-1058
nfoderaro@brewlife.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES